Donafenib

Donafenib, sold under the brand name Zepsun, is a pharmaceutical drug for the treatment of cancer.

In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment.

Donafenib is a kinase inhibitor that targets Raf kinase and various receptor tyrosine kinases. It is a deuterated derivative of sorafenib with improved pharmacokinetic properties.